Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE

Bibliographic Details
Main Authors:	Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael
Format:	Online
Language:	English
Published:	Springer Healthcare 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889314/

Similar Items

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
by: Östenson, Claes-Göran, et al.
Published: (2013)

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study
by: Reaney, Matthew, et al.
Published: (2013)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
by: Matthaei, Stephan, et al.
Published: (2012)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
by: Kiiskinen, Urpo, et al.
Published: (2013)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
by: Ji, Linong, et al.
Published: (2013)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
by: Henry, Robert R., et al.
Published: (2013)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
by: Ridge, T, et al.
Published: (2012)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
by: Davies, Melanie, et al.
Published: (2013)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
by: Tobin, G S, et al.
Published: (2012)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette, Elaine, et al.
Published: (2012)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
by: Inagaki, Nobuya, et al.
Published: (2011)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
by: Wolffenbuttel, B. H. R., et al.
Published: (2016)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
by: McDonell, Amanda L, et al.
Published: (2015)

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
by: Berg, J K, et al.
Published: (2011)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
by: Rosenstock, Julio, et al.
Published: (2012)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
by: Rosenstock, Julio, et al.
Published: (2013)

Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
by: Wenten, M, et al.
Published: (2012)

Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
by: Anichini, Roberto, et al.
Published: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
by: Alshali, Khalid Z., et al.
Published: (2016)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
by: Ciszek, Michał
Published: (2013)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
by: Rosenstock, Julio, et al.
Published: (2013)

Bimodal Solutions or Twice-Daily Icodextrin to Enhance Ultrafiltration in Peritoneal Dialysis Patients
by: Dousdampanis, Periklis, et al.
Published: (2013)

Twice-Daily Application of HIV Microbicides Alters the Vaginal Microbiota
by: Ravel, Jacques, et al.
Published: (2012)

Effect of Twice-Daily Blue Light Treatment on Matrix-Rich Biofilm Development
by: Lins de Sousa, Denise, et al.
Published: (2015)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Published: (2015)

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
by: MacConell, Leigh, et al.
Published: (2012)

Once bitten, twice shy: experienced regret and non-adaptive choice switching
by: Marcatto, Francesco, et al.
Published: (2015)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
by: Nachega, Jean B, et al.
Published: (2011)

Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.
by: McCormack, W M, et al.
Published: (1998)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock, Ashley, et al.
Published: (2011)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
by: Bunnapradist, S, et al.
Published: (2013)

Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism
by: Laliberté, François, et al.
Published: (2013)

Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease
by: Sakai, Yukinao, et al.
Published: (2013)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
by: Glick, Lauren, et al.
Published: (2014)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
by: Yun, Ji Young, et al.
Published: (2013)

Conversion from Twice-Daily to Once-Daily Tacrolimus Improves Graft Function but has no Influence on Proteinuria in Renal Transplant Recipients
by: Basic-Jukic Nikolina, et al.
Published: (2016-12-01)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance
by: Beeh, Kai-Michael, et al.
Published: (2016)

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
by: Šutalo, S., et al.
Published: (2015)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
by: Svedsater, Henrik, et al.
Published: (2016)